Cipla Limited — Important, 11-04-2025: Product launch

Cipla has announced a board meeting on the final approval received from the USFDA for its Abbreviated New Drug Application for Protein-bound Paclitaxel, an essential treatment for various cancers, including metastatic breast cancer. This product, an AB-rated generic equivalent of Bristol Myers Squibb’s Abraxane, is expected to launch in H1 FY 2025-26 in the U.S. This approval enhances Cipla's oncology portfolio and signifies potential revenue growth, positively impacting investor sentiment as the company strengthens its market presence in a crucial therapeutic area.